CIRM Funded Clinical Trials

A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants


Judith Shizuru
Investigator:
CIRM Grant:
Award Value:
$20,000,000
Trial Sponsor:
Trial Stage: 
Phase 1/2
Trial Status: 
Recruiting
Targeted Enrollment:
90
ClinicalTrials.gov ID:
Details: 

Monoclonal antibody that targets CD117 and promotes engraftment of hematopoietic stem cells. Could replace toxic conditioning regimens and enable chemotherapy-free transplants. Enabled donor cell HSC engraftment and cure of disease in an animal model of SCID.

Design: 

Open label, dose escalation trial

Goal: 

Safety. Dosing. Efficacy - HSC engraftment, immune reconstitution.

Status: 

Enrolling.